Literature DB >> 19880775

Blood cell activation in myeloproliferative neoplasms.

Francisco Cervantes, Eduardo Arellano-Rodrigo, Alberto Alvarez-Larrán.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19880775      PMCID： PMC2770957          DOI： 10.3324/haematol.2009.013375

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  29 in total

1.  Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.

Authors:  A Falanga; M Marchetti; V Evangelista; A Vignoli; M Licini; M Balicco; S Manarini; G Finazzi; C Cerletti; T Barbui
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

2.  Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count.

Authors:  M K Jensen; P de Nully Brown; B V Lund; O J Nielsen; H C Hasselbalch
Journal:  Eur J Haematol       Date:  2001-03       Impact factor: 2.997

3.  Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera.

Authors:  Alberto Alvarez-Larrán; Juan Carlos García-Pagán; Juan G Abraldes; Eduardo Arellano; Juan Carlos Reverter; Jaume Bosch; Francisco Cervantes
Journal:  Br J Haematol       Date:  2004-02       Impact factor: 6.998

4.  Enhanced generation of monocyte tissue factor and increased plasma prothrombin fragment1+2 levels in patients with polycythemia vera: mechanism of activation of blood coagulation.

Authors:  A Kornberg; N Rahimi-Levene; R Yona; A Mor; E A Rachmilewitz
Journal:  Am J Hematol       Date:  1997-09       Impact factor: 10.047

5.  Neutrophil functions in essential thrombocythemia.

Authors:  G Carulli; S Minnucci; A Azzara; M L Gianfaldoni; C Angiolini; A Sagripanti; A Ferretti; F Ambrogi
Journal:  Hematol Pathol       Date:  1995

6.  Increased neutrophil respiratory burst in myeloproliferative disorders: selective enhancement of superoxide release triggered by receptor-mediated agonists and low responsiveness to in vitro cytokine stimulation.

Authors:  S Iki; A Yuo; M Yagisawa; E K Inuo; Y Inoue; K Usuki; A Urabe; K Suzuki; S Kitagawa; A Togawa; F Takaku
Journal:  Exp Hematol       Date:  1997-01       Impact factor: 3.084

7.  Activated phenotype in neutrophils and monocytes from patients with primary proliferative polycythaemia.

Authors:  N B Westwood; E R Copson; L A Page; A R Mire-Sluis; K A Brown; T C Pearson
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

8.  The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera.

Authors:  Lisa Pieri; Costanza Bogani; Paola Guglielmelli; Maria Zingariello; Rosa Alba Rana; Niccolò Bartalucci; Alberto Bosi; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

9.  Increased CD11/CD18 expression and altered metabolic activity on polymorphonuclear leukocytes from patients with polycythemia vera and essential thrombocythemia.

Authors:  Carmen Burgaleta; Nuria González; Jesús César
Journal:  Acta Haematol       Date:  2002       Impact factor: 2.195

10.  Further studies of the defective stimulus-response coupling for the oxidative burst in neutrophils in polycythemia vera.

Authors:  J Samuelsson; A Berg
Journal:  Eur J Haematol       Date:  1991-10       Impact factor: 2.997
View more
  9 in total

1.  Pathophysiology of thrombosis in myeloproliferative neoplasms.

Authors:  Raffaele Landolfi; Leonardo Di Gennaro
Journal:  Haematologica       Date:  2011-02       Impact factor: 9.941

2.  JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation.

Authors:  Bärbel Edelmann; Nibedita Gupta; Tina M Schnoeder; Anja M Oelschlegel; Khurrum Shahzad; Jürgen Goldschmidt; Lars Philipsen; Soenke Weinert; Aniket Ghosh; Felix C Saalfeld; Subbaiah Chary Nimmagadda; Peter Müller; Rüdiger Braun-Dullaeus; Juliane Mohr; Denise Wolleschak; Stefanie Kliche; Holger Amthauer; Florian H Heidel; Burkhart Schraven; Berend Isermann; Andreas J Müller; Thomas Fischer
Journal:  J Clin Invest       Date:  2018-07-19       Impact factor: 14.808

3.  Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.

Authors:  Alberto Alvarez-Larrán; Manuel Pérez-Encinas; Francisca Ferrer-Marín; Juan Carlos Hernández-Boluda; María José Ramírez; Joaquín Martínez-López; Elena Magro; Yasmina Cruz; María Isabel Mata; Pilar Aragües; María Laura Fox; Beatriz Cuevas; Sara Montesdeoca; José Angel Hernández-Rivas; Valentín García-Gutiérrez; María Teresa Gómez-Casares; Juan Luis Steegmann; María Antonia Durán; Montse Gómez; Ana Kerguelen; Abelardo Bárez; Mari Carmen García; Concepción Boqué; José María Raya; Clara Martínez; Manuel Albors; Francesc García; Carmen Burgaleta; Carlos Besses
Journal:  Haematologica       Date:  2016-09-29       Impact factor: 9.941

4.  Splanchnic vein thrombosis, the onset manifestation in JAK positive Chronic Myeloproliferative Disorders Neoplasms.

Authors:  A M Vladareanu; V Popov; H Bumbea; M Onisai; A Ilea; C Dobrea; M Miulescu
Journal:  J Med Life       Date:  2011-02-25

5.  Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.

Authors:  Y Nakaya; K Shide; T Niwa; J Homan; S Sugahara; T Horio; K Kuramoto; T Kotera; H Shibayama; K Hori; H Naito; K Shimoda
Journal:  Blood Cancer J       Date:  2011-07-22       Impact factor: 11.037

6.  Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study.

Authors:  Daria Sollazzo; Dorian Forte; Nicola Polverelli; Marco Romano; Margherita Perricone; Lara Rossi; Emanuela Ottaviani; Simona Luatti; Giovanni Martinelli; Nicola Vianelli; Michele Cavo; Francesca Palandri; Lucia Catani
Journal:  Oncotarget       Date:  2016-07-12

7.  Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance.

Authors:  Saeid Shahrabi; Ali Ehsanpour; Somayyeh Heidary; Mohammad Shahjahani; Masumeh Maleki Behzad
Journal:  Oncol Rev       Date:  2018-10-02

8.  Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin?

Authors:  Alessandro Lucchesi; Silvia Carloni; Serena De Matteis; Martina Ghetti; Gerardo Musuraca; Monica Poggiaspalla; Accursio F Augello; Giulio Giordano; Pier P Fattori; Giovanni Martinelli; Roberta Napolitano
Journal:  Br J Haematol       Date:  2019-12-02       Impact factor: 6.998

9.  Mass Cytometry Phenotyping of Human Granulocytes Reveals Novel Basophil Functional Heterogeneity.

Authors:  Nora Vivanco Gonzalez; John-Paul Oliveria; Dmitry Tebaykin; Geoffrey T Ivison; Kaori Mukai; Mindy M Tsai; Luciene Borges; Kari C Nadeau; Stephen J Galli; Albert G Tsai; Sean C Bendall
Journal:  iScience       Date:  2020-10-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.